The fifth edition of the WHO Classification of Tumors of the Central NervousSystem (CNS), published in 2021, established new approaches to both CNS tumornomenclature and grading, emphasizing the importance of integrated diagnosesand layered reports. This edition increased the role of molecular diagnosticsin CNS tumor classification while still relying on other established approachessuch as histology and immunohistochemistry. Moreover, it introduced newtumor types and subtypes based on novel diagnostic technologies such as DNAmethylome profiling. Over the past decade, molecular techniques identifiednumerous key genetic alterations in CSN tumors, with important implicationsregarding the understanding of pathogenesis but also for prognosis and thedevelopment and application of effective molecularly targeted therapies. Thisreview summarizes the major changes in the 2021 fifth edition classification ofpediatric CNS tumors, highlighting for each entity the molecular alterations andother information that are relevant for diagnostic, prognostic, or therapeuticpurposes and that patients’ and oncologists’ need from a pathology report.
Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?
Evelina Miele;
2024-01-01
Abstract
The fifth edition of the WHO Classification of Tumors of the Central NervousSystem (CNS), published in 2021, established new approaches to both CNS tumornomenclature and grading, emphasizing the importance of integrated diagnosesand layered reports. This edition increased the role of molecular diagnosticsin CNS tumor classification while still relying on other established approachessuch as histology and immunohistochemistry. Moreover, it introduced newtumor types and subtypes based on novel diagnostic technologies such as DNAmethylome profiling. Over the past decade, molecular techniques identifiednumerous key genetic alterations in CSN tumors, with important implicationsregarding the understanding of pathogenesis but also for prognosis and thedevelopment and application of effective molecularly targeted therapies. Thisreview summarizes the major changes in the 2021 fifth edition classification ofpediatric CNS tumors, highlighting for each entity the molecular alterations andother information that are relevant for diagnostic, prognostic, or therapeuticpurposes and that patients’ and oncologists’ need from a pathology report.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

